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hlamydia, the leading sexually-transmitted
bacterial infection in the United States,
can cause severe health disorders including
inflammation of the cervix in women and the
urethra in men; pelvic inflammatory disease;
infertility and ectopic pregnancy; trachoma, a
preventable, blinding disease in underdeveloped
parts of the world; and an inflammatory reactive
arthritis.
A Wayne State University husband–wife team is
leading research to elucidate the molecular details of
the synovial, or joint-related, pathogenesis process
elicited by Chlamydia trachomatis, (C trachomatis),
as well as developing a vaccine to protect against
infection.
Alan Hudson, Ph.D. and Judith WhittumHudson, Ph.D., both professors of immunology and
microbiology in the Wayne State University School
of Medicine, have discovered that C trachomatis can
generate persistent, difficult to detect infections of
the synovium, the thin layer of tissue which lines
the joint space, causing reactive arthritis. Until
recently, such persistent infections had proven
resistant to antibiotics and other relevant therapies.
“We have discovered that, contrary to current
thinking, it is not genital strains of C trachomatis
that cause the inflammatory arthritis,” said Hudson.
“Rather, only trachoma strains known for causing
ocular disease, which are found in low numbers
in genital inocula, appear to disseminate from the
genital tract to the joint.”
Further studies in collaboration with a
rheumatologist/researcher at the University of
South Florida’s School of Medicine, demonstrated
for the first time that a combination antibiotic
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treatment, in lieu of single antibiotic treatment, is
effective in eliminating persistent C trachomatis in
the synovium. This has implications for treatment
of disseminated chlamydial infections at other
anatomic sites in addition to the synovium.
Taking a combined antimicrobial approach using
one antibiotic that inhibits RNA polymerase and
heat shock proteins along with another that inhibits
bacterial protein synthesis, eradication of persistent
chlamydiae may lead to improvement or possibly a
cure for the disease.
“Our data give hope for the development of
therapies to improve the clinical symptoms of
Chlamydia-induced reactive arthritis centered on
this new treatment approach,” said Hudson. “These
combined therapies may not only significantly
improve the treatment of persistent chlamydial
infections; they may also have important
implications in a number of other chronic
Chlamydia-related diseases.”

Getting closer to eliminating Chlamydia
After nearly four decades of research,
Whittum-Hudson’s research on chlamydial
immunopathogenesis and vaccine development
is beginning to pay off. She has developed and
characterized novel vaccine candidates against
chlamydial infections, and several patent
applications have been possible because of these
efforts.
Most recently Whittum-Hudson has identified
several peptides that have potential as vaccines
against Chlamydia. With many areas of the world
lacking access to basic health care and treatments
such as antibiotics, a new vaccine given orally or
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through intranasal delivery may offer more effective
protection against Chlamydia infections, ultimately
decreasing a significant number of cases of the
infection.
“I am also exploring novel combinations of
these and additional peptides that are mimotopes
for the carbohydrate associated with a chlamydial
glycolipid antigen,” said Whittum-Hudson.
“Because these peptides mimic the chlamydial
organism, they induce antibodies and other
immune responses that recognize the whole
organism and may allow them to serve as vaccine
candidates.” An important aspect of these vaccine
candidates is that they could protect against all
types of Chlamydia capable of infecting humans as
well as many animal species.
Using the same theory as vaccine delivery,
the duo is also working with researchers from
WSU’s Department of Chemical Engineering to
develop nanomedicine approaches to diagnose and
deliver therapy for Chlamydia-associated diseases,
particularly in the context of the inflammatory
reactive arthritis. These collaborations have led to
new nanomedicine endeavors with nanoparticles
and dendrimers that specifically target infected
cells for diagnosis and treatment of chlamydial
infections. New patent applications and grants have
resulted from these nanotechnology focused studies.
“These various research efforts demonstrate an
ongoing, upward trajectory in new approaches
to chlamydial research,” said Whittum-Hudson.
“Through this cutting-edge research, we are
closer to one day eliminating diseases caused by
Chlamydia.”
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About Dr. Judith Whittum-Hudson:

About Dr. Alan Hudson:

Dr. Whittum-Hudson received a B.A. in biology from Wells College
and a Ph.D. in pathology from the University of Connecticut. She
did postdoctoral research training at the University of Texas Health
Science Center. She joined Wayne State University in 1998.

Dr. Hudson received a B.A. in biology and chemistry from Hamilton College
and a Ph.D. in molecular biology from the City University of New York. He did
postdoctoral research training at the University of Paris and at the University
of Texas Health Sciences Center at Dallas. He joined Wayne State University
in 1997.
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